

Francis Buadi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8719336/publications.pdf>

Version: 2024-02-01

439
papers

10,531
citations

57631

44
h-index

42291

92
g-index

444
all docs

444
docs citations

444
times ranked

7910
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.	0.6	2,022
2	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. <i>Journal of Clinical Oncology</i> , 2012, 30, 989-995.	0.8	837
3	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
4	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
5	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 926-933.	1.4	240
6	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012, 119, 2100-2105.	0.6	218
7	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	6.3	187
8	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
9	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	1.4	164
10	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	0.8	161
11	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4529-4535.	0.8	147
12	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. <i>Blood</i> , 2012, 119, 5397-5404.	0.6	144
13	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. <i>Leukemia</i> , 2017, 31, 2791-2798.	3.3	120
14	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012, 119, 4860-4867.	0.6	119
15	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
16	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
17	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
18	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.	0.8	100

#	ARTICLE	IF	CITATIONS
19	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	1.4	92
20	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015, 5, e364-e364.	2.8	81
21	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
22	Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 87-93.	2.0	76
23	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
24	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75
25	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
26	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	3.3	72
27	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
28	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
29	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
30	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
31	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
32	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
33	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
34	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. <i>Bone Marrow Transplantation</i> , 2011, 46, 943-949.	1.3	57
35	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2012, 118, 6105-6109.	2.0	57
36	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57

#	ARTICLE	IF	CITATIONS
37	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92.	1.4	57
38	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
39	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.	2.8	56
40	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
41	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	0.8	53
42	Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). <i>European Journal of Haematology</i> , 2018, 100, 215-217.	1.1	52
43	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
44	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
45	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
46	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
47	Sporadic late-onset nemaline myopathy. <i>Neurology</i> , 2019, 93, e298-e305.	1.5	45
48	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
49	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	3.3	43
50	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
51	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
52	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
53	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
54	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38

#	ARTICLE	IF	CITATIONS
55	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
56	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
57	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	2.0	37
58	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
59	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 222-228.	2.0	36
60	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015, 56, 3357-3364.	0.6	36
61	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e363-e363.	2.8	36
62	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.	2.0	36
63	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
64	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
65	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
66	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
67	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
68	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
69	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , 2015, 126, 727-727.	0.6	32
70	Soluble suppression of tumorigenicity 2 (sT ₂), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
71	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8039-8039.	0.8	31
72	Clinical characteristics and outcomes in bclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30

#	ARTICLE	IF	CITATIONS
73	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
74	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.	1.7	29
75	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
76	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
77	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
78	POEMS Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 119-139.	0.9	28
79	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
80	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
81	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
82	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 3138-3138.	0.6	26
83	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
84	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
85	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
86	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
87	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
88	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
89	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
90	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	2.8	24

#	ARTICLE	IF	CITATIONS
91	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.1	23
92	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.	2.5	23
93	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.	2.5	23
94	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.4	22
95	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
96	Delineation of the timing of second-line therapy post ^o autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.	0.6	21
97	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
98	Implications of detecting serum monoclonal protein by MASS ^o fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
99	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
100	Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. <i>American Journal of Hematology</i> , 2017, 92, E15-E17.	2.0	20
101	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20
102	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
103	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
104	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 1106-1110.	2.0	19
105	Utility and prognostic value of ¹⁸ F ^o FDG positron emission tomography ^o computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.	2.0	19
106	Characteristics of late transplant ^o associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	2.0	19
107	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
108	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18

#	ARTICLE	IF	CITATIONS
109	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	2.8	18
110	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
111	A case of bilateral renal arterial thrombosis associated with cryocryoglobulinaemia. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 74-77.	1.4	17
112	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	0.6	17
113	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	1.2	17
114	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	2.0	17
115	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17
116	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 8001-8001.	0.8	17
117	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	0.6	16
118	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
119	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
120	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
121	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	0.6	16
122	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 2973-2973.	0.6	16
123	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	1.4	16
124	Elevation of serum lactate dehydrogenase in <i>AL</i> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
125	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.	1.2	15
126	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15

#	ARTICLE	IF	CITATIONS
127	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.	3.3	15
128	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
129	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
130	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	2.0	14
131	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.	2.0	14
132	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.	2.0	14
133	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	2.0	14
134	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.	1.3	13
135	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
136	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.	2.0	13
137	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	2.5	13
138	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	0.6	13
139	A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort. <i>Blood</i> , 2013, 122, 3179-3179.	0.6	13
140	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010, 116, 3554-3554.	0.6	13
141	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	2.5	13
142	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	1.2	12
143	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
144	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12

#	ARTICLE	IF	CITATIONS
145	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
146	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.	1.4	12
147	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
148	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 985-985.	0.6	12
149	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
150	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.	3.3	12
151	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
152	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
153	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , .	2.5	11
154	High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. <i>American Journal of Hematology</i> , 2011, 86, 554-558.	2.0	10
155	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2.	0.2	10
156	First report of MYD88^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.	1.4	10
157	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.	1.7	10
158	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.	2.0	10
159	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021, 11, 26.	2.8	10
160	Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021, 148, 2807-2814.	2.3	10
161	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 304-304.	0.6	10
162	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9

#	ARTICLE	IF	CITATIONS
163	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9
164	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
165	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
166	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.	2.0	9
167	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	1.3	9
168	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036.	2.5	9
169	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
170	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013, 122, 2151-2151.	0.6	9
171	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e569-e569.	2.8	8
172	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
173	Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. <i>Neurology</i> , 2018, 90, 748-752.	1.5	8
174	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159.	2.0	8
175	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.2	8
176	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	1.3	8
177	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	2.8	8
178	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326.	2.5	8
179	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8
180	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8

#	ARTICLE	IF	CITATIONS
181	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
182	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	0.6	8
183	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	0.6	8
184	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	2.8	8
185	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . Leukemia, 2022, 36, 1429-1431.	3.3	8
186	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	1.3	7
187	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	2.0	7
188	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	3.3	7
189	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	1.3	7
190	Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. Leukemia and Lymphoma, 2019, 60, 1275-1282.	0.6	7
191	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	0.6	7
192	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	0.6	7
193	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.4	7
194	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
195	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	2.5	7
196	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	0.6	6
197	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood, 2018, 132, 123-123.	0.6	6
198	Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. Blood, 2008, 112, 2744-2744.	0.6	6

#	ARTICLE	IF	CITATIONS
199	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3572-3572.	0.6	6
200	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
201	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809.	1.3	6
202	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
203	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
204	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935.	1.3	5
205	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.4	5
206	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010, 116, 1964-1964.	0.6	5
207	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 3031-3031.	0.6	5
208	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
209	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5
210	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8002-8002.	0.8	5
211	Supportive care in multiple myeloma: Current practices and advances. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100476.	0.7	5
212	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010, 116, 2253-2253.	0.6	5
213	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4120-4120.	0.6	5
214	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	2.0	5
215	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
216	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4

#	ARTICLE	IF	CITATIONS
217	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	1.4	4
218	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
219	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
220	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
221	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.	2.0	4
222	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.	1.1	4
223	Case vignettes and other brain teasers of monoclonal gammopathies. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 582-585.	0.9	4
224	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.	0.6	4
225	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4
226	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
227	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 370-370.	0.6	4
228	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years. <i>Blood</i> , 2011, 118, 3963-3963.	0.6	4
229	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
230	Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM). <i>Journal of Clinical Oncology</i> , 2016, 34, 8058-8058.	0.8	4
231	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). <i>Journal of Clinical Oncology</i> , 2019, 37, 7509-7509.	0.8	4
232	Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. <i>American Journal of Hematology</i> , 2016, 91, E5-E6.	2.0	3
233	Serum free light chain measurements to reduce 24h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3
234	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3

#	ARTICLE	IF	CITATIONS
235	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
236	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.1	3
237	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	0.6	3
238	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
239	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. Blood, 2008, 112, 95-95.	0.6	3
240	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 2868-2868.	0.6	3
241	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	0.6	3
242	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	0.6	3
243	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	0.6	3
244	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	0.6	3
245	Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.	0.6	3
246	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	0.6	3
247	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.	0.8	3
248	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	0.6	3
249	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
250	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3
251	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Advances, 2022, 6, 5429-5435.	2.5	3
252	Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. Journal of Cutaneous Pathology, 2017, 44, 1087-1091.	0.7	2

#	ARTICLE	IF	CITATIONS
253	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
254	Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
255	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
256	Reply to: Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021, 149, 743-744.	2.3	2
257	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
258	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
259	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	0.6	2
260	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
261	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
262	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
263	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. <i>Blood</i> , 2010, 116, 1892-1892.	0.6	2
264	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011, 118, 2942-2942.	0.6	2
265	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012, 120, 1858-1858.	0.6	2
266	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	0.6	2
267	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
268	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19519-e19519.	0.8	2
269	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. <i>Blood</i> , 2010, 116, 1942-1942.	0.6	2
270	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , 2011, 118, 1875-1875.	0.6	2

#	ARTICLE	IF	CITATIONS
271	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
272	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
273	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	2.0	2
274	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Oncology and Therapy</i> , 2022, 10, 105-122.	1.0	2
275	Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 43.	2.0	1
276	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
277	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a $\tilde{\text{graft}}$ versus host $\tilde{\text{TM}}$ -like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 1879-1881.	1.3	1
278	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
279	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
280	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	0.6	1
281	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
282	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
283	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
284	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007, 110, 2477-2477.	0.6	1
285	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009, 114, 956-956.	0.6	1
286	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. <i>Blood</i> , 2010, 116, 1893-1893.	0.6	1
287	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010, 116, 3557-3557.	0.6	1
288	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. <i>Blood</i> , 2010, 116, 863-863.	0.6	1

#	ARTICLE	IF	CITATIONS
289	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011, 118, 2887-2887.	0.6	1
290	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. <i>Blood</i> , 2011, 118, 2950-2950.	0.6	1
291	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 3095-3095.	0.6	1
292	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. <i>Blood</i> , 2011, 118, 806-806.	0.6	1
293	Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.. <i>Blood</i> , 2012, 120, 2965-2965.	0.6	1
294	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. <i>Blood</i> , 2012, 120, 3992-3992.	0.6	1
295	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	0.6	1
296	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1
297	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	0.6	1
298	Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients. <i>Blood</i> , 2015, 126, 3046-3046.	0.6	1
299	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	0.6	1
300	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	0.6	1
301	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
302	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
303	Outcomes of young patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8609-8609.	0.8	1
304	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8015-8015.	0.8	1
305	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.	0.8	1
306	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. <i>Blood</i> , 2010, 116, 2970-2970.	0.6	1

#	ARTICLE	IF	CITATIONS
307	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. Blood, 2010, 116, 987-987.	0.6	1
308	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.	0.8	1
309	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.	0.6	1
310	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	0.8	1
311	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
312	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
313	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
314	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
315	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	0.6	1
316	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	0.6	1
317	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	0.6	1
318	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	0.6	1
319	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	0.6	1
320	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. Journal of Clinical Oncology, 2020, 38, e20510-e20510.	0.8	1
321	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	0.6	1
322	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	0.6	1
323	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	0.6	1
324	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2021, 39, e20016-e20016.	0.8	0
326	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. Blood, 2007, 110, 3608-3608.	0.6	0
327	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	0.6	0
328	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	0.6	0
329	Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males.. Blood, 2007, 110, 960-960.	0.6	0
330	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. Blood, 2008, 112, 2301-2301.	0.6	0
331	The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. Blood, 2008, 112, 5114-5114.	0.6	0
332	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	0.6	0
333	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	0.6	0
334	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. Blood, 2010, 116, 3047-3047.	0.6	0
335	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. Blood, 2010, 116, 4518-4518.	0.6	0
336	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. Blood, 2010, 116, 3468-3468.	0.6	0
337	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. Blood, 2010, 116, 1958-1958.	0.6	0
338	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. Blood, 2010, 116, 3469-3469.	0.6	0
339	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	0.6	0
340	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	0.6	0
341	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.	0.6	0
342	IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	0.6	0
344	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 600-600.	0.6	0
345	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012, 120, 599-599.	0.6	0
346	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1988-1988.	0.6	0
347	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	0.6	0
348	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3209-3209.	0.6	0
349	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 754-754.	0.6	0
350	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. <i>Blood</i> , 2013, 122, 1928-1928.	0.6	0
351	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. <i>Blood</i> , 2013, 122, 1842-1842.	0.6	0
352	Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8594-8594.	0.8	0
353	Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11085-11085.	0.8	0
354	Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8595-8595.	0.8	0
355	Survival trends in young patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8596-8596.	0.8	0
356	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3039-3039.	0.6	0
357	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	0.6	0
358	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	0.6	0
359	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044.	0.6	0
360	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8033-8033.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8053-8053.	0.8	0
362	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8017-8017.	0.8	0
363	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.	0.8	0
364	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.	0.8	0
365	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0
366	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996.	0.6	0
367	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	0.6	0
368	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	0.6	0
369	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	0.6	0
370	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	0.6	0
371	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	0.6	0
372	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	0.6	0
373	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	0.6	0
374	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	0.6	0
375	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	0.6	0
376	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	0.6	0
377	The use of proteasome inhibitors among patients with POEMS syndrome.. Journal of Clinical Oncology, 2017, 35, e19530-e19530.	0.8	0
378	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. Journal of Clinical Oncology, 2017, 35, 8020-8020.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. Journal of Clinical Oncology, 2017, 35, e19532-e19532.	0.8	0
380	Natural history of del53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	0.8	0
381	Predictors of disease progression in smoldering Waldenström macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 7571-7571.	0.8	0
382	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
383	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
384	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
385	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
386	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
387	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
388	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
389	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
390	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
391	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
392	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
393	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
394	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0
395	Immune System Profiling of Waldenström Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	0.6	0
396	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.	0.6	0
398	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
399	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8011-8011.	0.8	0
400	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.	0.6	0
401	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	0.6	0
402	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
403	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	0.6	0
404	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	0.6	0
405	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
406	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
407	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
408	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
409	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20506-e20506.	0.8	0
410	Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8549-8549.	0.8	0
411	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20515-e20515.	0.8	0
412	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.	0.5	0
413	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	0.6	0
414	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	0.6	0
416	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥ 100 . Blood, 2021, 138, 1617-1617.	0.6	0
417	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	0.6	0
418	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	0.6	0
419	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	0.6	0
420	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	0.6	0
421	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	0.6	0
422	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	0.6	0
423	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	0.6	0
424	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	0.6	0
425	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	0.6	0
426	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0
427	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	0.6	0
428	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
429	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. Blood, 2020, 136, 34-35.	0.6	0
430	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
431	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
432	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	0.6	0
434	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
435	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0
436	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
437	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0
438	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0
439	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0